论文部分内容阅读
目的研究复方甘草酸苷(SNMC)联合还原型谷胱甘肽治疗重症肝炎的治疗作用,提高临床效果、降低死亡率。方法观察组SNMC40~100ml加入5%葡萄糖注射液250ml静脉滴注,每日1次,还原型谷胱甘肽0.6~1.2g加入5%或10%葡萄糖250ml静脉滴注,每日1次,1个月为1个疗程,根据病情不同用1~3个疗程。对照组:甘利欣150~200mg加入5%或10%葡萄糖250ml静脉滴注,每日1次,促肝细胞生长素80~120mg加入5%或10%葡萄糖250ml静脉滴注,每日1次,余同观察组。结果80例显效46例,有效26例,总有效率92.5%,较对照组77.25%提高15.95%,肝功能比较,观察组ALT恢复至(45.2±6.3),TBIL恢复至(24.4±5.2)。对照组分别为(96.8±8.6)和(56.8±16.2),(P<0.05)。乙肝HBV-M检测,观察组HBeAg阴转率63.9%,抗HBs阳转率39.0%,对照组分别为42.42%和17.14%(P<0.01)。肝纤维化标志,观察组HA、LN恢复分别为(78.2±59.6),(79.3±41.8),对照组恢复分别为(86.6±96.8),(156.3±58.3)(P<0.01)。结论SNMC联合还原型谷胱甘肽治疗重症肝炎资料显示,观察组优于对照组,是治疗重症肝炎,特别是亚急性重症肝炎和慢性重症肝炎的理想方案之一。
Objective To study the therapeutic effect of compound glycyrrhizin (SNMC) combined with reduced glutathione on severe hepatitis to improve the clinical effect and reduce the mortality rate. Methods The observation group SNMC 40 ~ 100ml added 5% glucose injection 250ml intravenous infusion, once daily, reduced glutathione 0.6 ~ 1.2g by adding 5% or 10% glucose 250ml intravenous infusion, 1 day, 1 Month for a course of treatment, according to the different conditions with 1 to 3 courses. Control group: Glycyrrhizin 150 ~ 200mg by adding 5% or 10% glucose 250ml intravenous drip once a day, promoting hepatocyte growth factor 80 ~ 120mg add 5% or 10% glucose 250ml intravenous infusion, once daily, Yu Tong observation team. Results Eighty cases were markedly effective in 46 cases and effective in 26 cases. The total effective rate was 92.5%, which was 15.95% higher than 77.25% in control group. The liver function of ALT recovered to (45.2 ± 6.3) and (24.4 ± 5.2) in observation group. The control group were (96.8 ± 8.6) and (56.8 ± 16.2), respectively (P <0.05). Hepatitis B virus was detected by HBV-M. The HBeAg negative conversion rate and anti-HBs positive rate were 63.9% and 39.0% in the observation group and 42.42% and 17.14% respectively in the control group (P <0.01). The signs of liver fibrosis in the observation group were (78.2 ± 59.6) and (79.3 ± 41.8), respectively, and those in the control group were (86.6 ± 96.8) and (156.3 ± 58.3), respectively (P <0.01). Conclusion SNMC combined with reduced glutathione for the treatment of severe hepatitis shows that the observation group is superior to the control group and is an ideal treatment for severe hepatitis, especially sub-acute severe hepatitis and chronic severe hepatitis.